Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response to Moderna COVID-19 vaccination in stable kidney transplant recipients
2021-002014-14Phase 4Completed
- Sponsor
- Fakultní nemocnice Hradec Králové
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of elasomeran in coronavirus disease 2019 (COVID-19), sponsored by Fakultní nemocnice Hradec Králové. Primary endpoint: Antibody and cellular response at 33 weeks after second dose. Started Apr 2021; status: completed.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-002014-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002014-14.